Phosphodiesterase 4 inhibitors reduce human dendritic cell inflammatory cytokine production and Th 1-polarizing capacity

International Immunology

Volumn 15, Issue 7, 2003, Pages 827-835

  Heystek, Heleen C ^a,b   Thierry, Anne Christine ^a   Soulard, Patricia ^a   Moulon, Corinne ^a  

^a PFIZER INC   (United States)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Dendritic cell; Human; Inflammation; Th1; Th2

Indexed keywords

4,5 DIHYDRO 6 [4 (1H IMIDAZOL 1 YL)PHENYL] 5 METHYL 3(2H) PYRIDAZINONE; 6 [4 (1,4 DIHYDRO 4 OXO 1 PYRIDYL)PHENYL] 4,5 DIHYDRO 5 METHYL 3(2H) PYRIDAZINONE; AUTACOID; CD40 LIGAND; CHEMOKINE RECEPTOR CXCR4; CILOMILAST; CYCLIC AMP; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 12; LIPOPOLYSACCHARIDE; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV INHIBITOR; PROTEIN P70; ROLIPRAM; TUMOR NECROSIS FACTOR ALPHA; VINPOCETINE;

CELL COUNT; CELL MATURATION; CELL POLARITY; CELL PROLIFERATION; CELL STIMULATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG EXPOSURE; DRUG INDICATION; ENZYME ACTIVITY; ENZYME SPECIFICITY; ENZYME SUBUNIT; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOMODULATION; MEDIATOR RELEASE; MONOCYTE; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH1 CELL; TIME;

EID: 0037674864     PISSN: 09538178     EISSN: None     Source Type: Journal    
DOI: 10.1093/intimm/dxg079     Document Type: Review

References (56)

1. Simonds, W. F. 1999. G protein regulation of adenylate cyclase. Trends Pharmacol. Sci. 20:66.
2. Houslay, M. D. and Milligan, G. 1997. Tailoring cAMP-signalling responses through isoform multiplicity. Trends Biochem. Sci. 22:217.
3. Torphy, T. J. 1998. Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. Am. J. Respir. Crit. Care. Med. 157:351.
4. Essayan, D. M. 1999. Cyclic nucleotide phosphodiesterase (PDE) inhibitors and immunomodulation. Biochem. Pharmacol. 57:965.
5. Doherty, A. M. 1999. Phosphodiesterase 4 inhibitors as novel anti-inflammatory agents. Curr. Opin. Chem. Biol. 3:466.
6. Griswold, D. E., Webb, E. F., Badger, A. M., Gorycki, P. D., Levandoski, P. A., Barnette, M. A., Grous, M., Christensen, S. and Torphy, T. J. 1998. SB 207499 (Ariflo), a second generation phosphodiesterase 4 inhibitor, reduces tumor necrosis factor alpha and interleukin-4 production in vivo. J. Pharmacol. Exp. Ther. 287:705.
7. Teixeira, M. M., Gristwood, R. W., Cooper, N. and Hellewell, P. G. 1997. Phosphodiesterase (PDE)4 inhibitors: anti-inflammatory drugs of the future? Trends Pharmacol. Sci. 18:164.
8. Banchereau, J. and Steinman, R. M. 1998. Dendritic cells and the control of immunity. Nature 392:245.
9. Sallusto, F., Cella, M., Danieli, C. and Lanzavecchia, A. 1995. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J. Exp. Med. 182:389.
10. Cella, M., Scheidegger, D., Palmer Lehmann, K., Lane, P., Lanzavecchia, A. and Alber, G. 1996. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J. Exp. Med. 184:747.
11. Sallusto, F. and Lanzavecchia, A. 1994. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α. J. Exp. Med. 179:1109.
12. Verhasselt, V., Buelens, C., Willems, F., De Groote, D., Haeffner-Cavaillon, N. and Goldman, M. 1997. Bacterial lipopolysaccharide stimulates the production of cytokines and the expression of costimulatory molecules by human peripheral blood dendritic cells. Evidence for a soluble CD14-dependent pathway. J. Immunol. 158:2919.
13. Trinchieri, G. and Scott, P. 1994. The role of interleukin 12 in the immune response, disease and therapy. Immunol. Today 15:460.
14. h1 development by selective inhibition of interleukin 12. J. Clin. Invest 100:1513.
15. Vieira, P. L., Kalinski, P., Wierenga, E. A., Kapsenberg, M. L. and de Jong, E. C. 1998. Glucocorticoids inhibit bioactive IL-12p70 production by in vitro-generated human dendritic cells without affecting their T cell stimulatory potential. J. Immunol. 161:5245.
16. Smith, B. J., Wales, M. R., Jappy, J. W. and Perry, M. J. 1993. A phosphodiesterase assay using alumina microcolumns. Anal. Biochem. 214:355.
17. Hagiwara, M., Endo, T. and Hidaka, H. 1984. Effects of vinpocetine on cyclic nucleotide metabolism in vascular smooth muscle. Biochem. Pharmacol. 33:453.
18. Murray, K. J., Eden, R. J., Dolan, J. S., Grimsditch, D. C., Stutchbury, C. A., Patel, B., Knowles, A., Worby, A., Lynham, J. A. and Coates, W. J. 1992. The effect of SK&F 95654, a novel phosphodiesterase inhibitor, on cardiovascular, respiratory and platelet function. Br. J. Pharmacol. 107:463.
19. h1-mediated autoimmune diseases. J. Immunol. 164:1117.
20. + dendritic cells: the levels of IL-12 are determined during the final dendritic cell maturation and are resistant to further modulation. J. Immunol. 161:2804.
21. h1-inducing capacity in myeloid dendritic cells requires environmental instruction. J. Immunol. 164:4507.
22. Gantner, F., Schudt, C., Wendel, A. and Hatzelmann, A. 1999. Characterization of the phosphodiesterase (PDE) pattern of in vitro-generated human dendritic cells (DC) and the influence of PDE inhibitors on DC function. Pulm. Pharmacol. Ther. 12:377.
23. Gantner, F., Tenor, H., Gekeler, V., Schudt, C., Wendel, A. and Hatzelmann, A. 1997. Phosphodiesterase profiles of highly purified human peripheral blood leukocyte populations from normal and atopic individuals: a comparative study. J. Allergy Clin. Immunol. 100:527.
24. + T-lymphocytes: role in regulating proliferation and the biosynthesis of interleukin. Br. J. Pharmacol. 118:1945.
25. Wang, P., Wu, P., Ohleth, K. M., Egan, R. W. and Billah, M. M. 1999. Phosphodiesterase 4B2 is the predominant phosphodiesterase species and undergoes differential regulation of gene expression in human monocytes and neutrophils. Mol. Pharmacol. 56:170.
26. Ma, D., Wu, P., Egan, R. W., Billah, M. M. and Wang, P. 1999. Phosphodiesterase 4B gene transcription is activated by lipopolysaccharide and inhibited by interleukin-10 in human monocytes. Mol. Pharmacol. 55:50.
27. Pette, M., Muraro, P. A., Pette, D. F., Dinter, H., McFarland, H. F. and Martin, R. 1999. Differential effects of phosphodiesterase type 4-specific inhibition on human autoreactive myelin-specific T cell clones. J. Neuroimmunol. 98:147.
28. Seldon, P. M., Barnes, P. J., Meja, K. and Giembycz, M. A. 1995. Suppression of lipopolysaccharide-induced tumor necrosis factor-α generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: interaction with stimulants of adenylyl cyclase. Mol. Pharmacol.48:747.
29. Prabhakar, U., Lipshutz, D., Bartus, J. O., Slivjak, M. J., Smith, E. F., III, Lee, J. C. and Esser, K. M. 1994. Characterization of cAMP-dependent inhibition of LPS-induced TNF α production by rolipram, a specific phosphodiesterase IV (PDE IV) inhibitor. Int. J. Immunopharmacol. 16:805.
30. Gantner, F., Kupferschmidt, R., Schudt, C., Wendel, A. and Hatzelmann, A. 1997. In vitro differentiation of human monocytes to macrophages: change of PDE profile and its relationship to suppression of tumour necrosis factor-α release by PDE inhibitors. Br. J. Pharmacol. 121:221.
31. h1 activity, and amelioration of collagen-induced arthritis by rolipram. J. Immunol. 159:6253.
32. Hatzelmann, A. and Schudt, C. 2001. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J. Pharmacol. Exp. Ther. 297:267.
33. Kambayashi, T., Wallin, R. P. and Ljunggren, H. G. 2001. cAMP-elevating agents suppress dendritic cell function. J. Leukoc. Biol. 70:903.
34. Liang, L., Beshay, E. and Prud'homme, G. J. 1998. The phosphodiesterase inhibitors pentoxifylline and rolipram prevent diabetes in NOD mice. Diabetes 47:570.
35. Santamaria, L. F., Torres, R., Gimenez-Arnau, A. M., Gimenez-Camarasa, J. M., Ryder, H., Palacios, J. M. and Beleta, J. 1999. Rolipram inhibits staphylococcal enterotoxin B-mediated induction of the human skin-homing receptor on T lymphocytes. J. Invest. Dermatol. 113:82.
36. Hasko, G., Szabo, C., Nemeth, Z. H., Salzman, A. L. and Vizi, E. S. 1998. Suppression of IL-12 production by phosphodiesterase inhibition in murine endotoxemia is IL-10 independent. Eur. J. Immunol. 28:468.
37. Kambayashi, T., Jacob, C. O., Zhou, D., Mazurek, N., Fong, M. and Strassmann, G. 1995. Cyclic nucleotide phosphodiesterase type IV participates in the regulation of IL-10 and in the subsequent inhibition of TNF-α and IL-6 release by endotoxin-stimulated macrophages. J. Immunol. 155:4909.
38. Eigler, A., Siegmund, B., Emmerich, U., Baumann, K. H., Hartmann, G. and Endres, S. 1998. Anti-inflammatory activities of cAMP-elevating agents: enhancement of IL-10 synthesis and concurrent suppression of TNF production. J. Leukoc. Biol. 63:101.
39. 2 receptors. J. Clin. Invest. 102:1866.
40. 2 is a potent inhibitor of human interleukin 12 production. J. Exp. Med. 181:775.
41. Maida, E. and Kristoferitsch, W. 1981. Cyclic adenosine 3′,5′ monophosphate in cerebrospinal fluid of multiple sclerosis patients. J. Neurol. 225:145.
42. Lombardi, M. S., Kavelaars, A., Schedlowski, M., Bijlsma, J. W., Okihara, K. L., Van de, P. M., Ochsmann, S., Pawlak, C., Schmidt, R. E. and Heijnen, C. J. 1999. Decreased expression and activity of G-protein-coupled receptor kinases in peripheral blood mononuclear cells of patients with rheumatoid arthritis. FASEB. J. 13:715.
43. Haraguchi, S., Good, R. A. and Day, N. K. 1995. Immunosuppressive retroviral peptides: cAMP and cytokine patterns. Immunol. Today 16:595.
44. Murphy, T. L., Cleveland, M. G., Kulesza, P., Magram, J. and Murphy, K. M. 1995. Regulation of interleukin 12 p40 expression through an NF-kappa B half-site. Mol. Cell. Biol. 15:5258.
45. Ma, X., Chow, J. M., Gri, G., Carra, G., Gerosa, F., Wolf, S. F., Dzialo, R. and Trinchieri, G. 1996. The interleukin 12 p40 gene promoter is primed by interferon gamma in monocytic cells. J. Exp. Med. 183:147.
46. Jongeneel, C. V. 1994. Regulation of the TNF α gene. Prog. Clin. Biol. Res. 388:367.
47. MacKenzie, S. J. and Houslay, M. D. 2000. Action of rolipram on specific PDE4 cAMP phosphodiesterase isoforms and on the phosphorylation of cAMP-response-element-binding protein (CREB) and p38 mitogen-activated protein (MAP) kinase in U937 monocytic cells. Biochem. J. 347:571.
48. h2 priming. Eur. J. Immunol. 30:2394.
49. h2-mediated responses. Immunol. Today 19:568.
50. Essayan, D. M., Huang, S. K., Kagey-Sobotka, A. and Lichtenstein, L. M. 1997. Differential efficacy of lymphocyte- and monocyte-selective pretreatment with a type 4 phosphodiesterase inhibitor on antigen-driven proliferation and cytokine gene expression. J. Allergy Clin. Immunol. 99:28.
51. h2 cell-promoting effector dendritic cells. J. Immunol. 167:3682.
52. 2, promote type 2 cytokine production in maturing human naïve T helper cells. J. Immunol. 159:28.
53. Sekut, L., Yarnall, D., Stimpson, S. A., Noel, L. S., Bateman-Fite, R., Clark, R. L., Brackeen, M. F., Menius, J. A., Jr and Connolly, K. M. 1995. Anti-inflammatory activity of phosphodiesterase (PDE)-IV inhibitors in acute and chronic models of inflammation. Clin. Exp. Immunol. 100:126.
54. Sommer, N., Loschmann, P. A., Northoff, G. H., Weller, M., Steinbrecher, A., Steinbach, J. P., Lichtenfels, R., Meyermann, R., Riethmuller, A. and Fontana, A. 1995. The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis. Nat. Med. 1:244.
55. Navikas, V., Matusevicius, D., Soderstrom, M., Pirskanen, R., Fredrikson, S. and Link, H. 1998. The phosphodiesterase IV inhibitor rolipram in vitro reduces the numbers of MBP-reactive IFN-gamma and TNF-alpha mRNA expressing blood mononuclear cells in patients with multiple sclerosis. Clin. Neuropharmacol. 21:236.
56. Rieckmann, P., Weber, F., Gunther, A., Martin, S., Bitsch, A., Broocks, A., Kitze, B., Weber, T., Borner, T. and Poser, S. 1996. Pentoxifylline, a phosphodiesterase inhibitor, induces immune deviation in patients with multiple sclerosis. J. Neuroimmunol. 64:193.